To access this element change to forms mode OFF
Grant Award View - GA201622
A curative approach for chronic myeloid leukaemia
GA ID:
GA201622
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
19-Aug-2021
Publish Date:
10-Nov-2021
Category:
Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2026
Value (AUD):
$2,241,612.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Investigator Grants
Grant Activity:
A curative approach for chronic myeloid leukaemia
Purpose:
Patients with chronic myeloid leukaemia (CML) still have adverse outcomes in 2021 with the majority requiring ongoing toxic therapy to control their disease. My program will focus on improving outcomes by determining the key genetic events driving drug resistance and disease progression, further developing the new, highly targeted drug asciminib which promises to revolutionise CML therapy, and remove the current barriers to treatment free remission, the ultimate goal of CML therapy today.
GO ID:
GO Title:
Investigator Grants 2021
Internal Reference ID:
2021/GNT2007908
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The University of Adelaide
Recipient ABN:
61 249 878 937
Grant Recipient Location
Suburb:
Adelaide
Town/City:
Adelaide
Postcode:
5000
State/Territory:
SA
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
SA
Postcode:
Country:
AUSTRALIA